Claudiu Diaconu, MD
Neurology · White Plains, NYNPI 1205271715
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,600 of the $2,285 with a category attached, or 70.0%. EMD Serono, Inc. accounts for 70.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $1,600 and has fallen 93.3% since, to $107 in 2025.
Across 19 payments — averaging $120.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$2K
- Biogen$211
- Novartis$195
- Inspire Medical Systems, Inc.$112
- Medtronic$111
- CSL Behring$23
- plus $33 from 2 others
What the payments were for
- Consulting fees$1,60070%
- Food & beverage$63028%
- Education$562%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 1 | $1,600 |
| Biogen | 5 | $211 |
| Novartis | 8 | $195 |
| Inspire Medical Systems, Inc. | 1 | $112 |
| Medtronic | 1 | $111 |
| CSL Behring | 1 | $23 |
| Lilly USA, LLC | 1 | $17 |
| Strongbridge US Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,285 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 13 | $129,693 |
| Rivastigmine | 12 | $3,278 |
| Gabapentin | 83 | $2,113 |
| Pregabalin | 43 | $1,728 |
| Donepezil Hcl | 138 | $1,268 |
| Memantine Hcl | 64 | $927 |
| AmantadineAmantadine Hcl | 17 | $896 |
| Duloxetine Hcl | 34 | $880 |
| Quetiapine Fumarate | 25 | $585 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 18 | $531 |
| Bupropion XlBupropion Hcl | 11 | $472 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $470 |
| Propranolol Hcl | 17 | $417 |
| Sumatriptan Succinate | 21 | $364 |
| Nortriptyline Hcl | 13 | $321 |
Paid to pharmacies, not to this prescriber.
Other neurology in White Plains
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.